Eye injections or steroid implant to prevent vision loss
Treatments studied
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial studies ways to prevent worsening vision caused by radiation damage to the retina after plaque brachytherapy for uveal melanoma. You may be randomly assigned to a medication injection, a steroid implant, or observation to see which approach best protects vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary uveal melanoma (not iris melanoma) and are getting plaque brachytherapy first treatment
- Your vision loss is not from another unrelated eye problem
- Your starting vision is at least 20/200 (about 34 letters or better)
- The tumor is not centered under the macula (fovea) and not touching the optic disc
- Your planned radiation dose to the macula is at least 30 Gy
- You can complete fluorescein angiography testing (a dye-based eye scan)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radiation treatment for people with wet age-related macular degeneration (AMD) that hasn't fully responded to standard eye injections. The treatment aims to reduce the need for ongoing injections and help maintain vision.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
This trial tests whether a single steroid injection around the back of the eye can improve vision in people with diabetic macular edema (swelling in the center of the retina that blurs vision). It is for people who have not yet had any other eye treatments for this condition.
This study tests whether a steroid injection behind the eye (a retrobulbar injection) can help people whose retina (the light-sensing layer at the back of the eye) has been damaged by looking at a strong light source, like a laser or bright flash. The treatment aims to reduce swelling and vision problems that can follow such an injury.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Hear when a new Visual Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.